RxDoctor Payments Data

Farhana Hasan, MD

Dermatology · Columbus, OHNPI 1922193663

Payments from drug & device makers

$3,807in general payments, 2019–2025

Across 169 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$925
  • E.r. Squibb & Sons, L.L.C.$628
  • Regeneron Healthcare Solutions, Inc.$485
  • AbbVie$374
  • Novartis$345
  • Amgen$157
  • plus $894 from 16 others

What the payments were for

  • Food & beverage$3,44691%
  • Education$3619%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,807 in reported general payments places this provider in the 55th percentile of 460 dermatology providers in Ohio.

See all dermatology providers in Ohio

Medicare billing

Part B allowed, 2024
$133,884
Medicare patients
519
Services billed
2,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab23$313,946
Humira(Cf) PenAdalimumab14$179,114
Cosentyx Unoready PenSecukinumab14$104,255
Taltz SyringeIxekizumab14$95,677
Fluorouracil68$4,815
Mycophenolate Mofetil24$3,538
Clobetasol Propionate73$3,498
Triamcinolone Acetonide200$2,445
Doxycycline Hyclate130$2,354
Ketoconazole77$1,304
Calcipotriene12$926
Metronidazole11$603
Hydrocortisone80$434
MethotrexateMethotrexate Sodium23$275
ValacyclovirValacyclovir Hcl22$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$925$313,94623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 460 dermatology providers in Ohio.

Other dermatology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →